Q BioMed Inc

Change company Symbol lookup

Select an option...

QBIO Q BioMed Inc

FRZA Forza X1 Inc

ILMN Illumina Inc

NR Newpark Resources Inc

CGC Canopy Growth Corp

NAOV Nanovibronix Inc

ETON Eton Pharmaceuticals Inc

LXRX Lexicon Pharmaceuticals Inc

BVS Bioventus Inc

TDS-U Telephone and Data Systems Inc

Go

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.